Trastuzumab has been electrostatically adsorbed on the surface of these NPs as a ligand targeting human epidermal growth factor receptor 2 (HER2)-positive breast cancer cells, while Docetaxel is entrapped in core NPs. This evidence concerns the gene ERBB2 and breast cancer.